Humanized neutralizing antibody (RVFab3) against rabies virus glycoprotein

Abstract

The invention discloses a humanized neutralizing antibody (RVFab3) against rabies virus glycoprotein, which is obtained through screening by utilizing phage display technology. The antibody specifically identifies the granule antigen of the rabies virus, is against the rabies virus glycoprotein G, has obvious immunofluorescence reaction and enzyme linked immunosorbent assay with the rabies virus and has the neutralizing activity function against rabies virus infection. The antibody can be prepared into the specific antibody drugs for preventing and treating rabies, thereby being clinically used for preventing and treating rabies caused by the rabies virus.

Description

technical field The invention relates to genetic engineering antibody technology, in particular to a human-source neutralizing antibody against rabies virus glycoprotein; the invention also relates to the application of the antibody in the preparation of medicaments for preventing or treating rabies. Background technique Rabies is a worldwide zoonotic disease caused by rabies virus, once the onset of 100% death. Rabies has been reported in 87 countries in the world, and more than 50,000 people die from rabies every year (Knobel DL, et al.2005). Rabies post-exposure prophylaxis is the main measure to prevent and control rabies. For severely exposed people, the World Health Organization (WHO) recommends the use of rabies vaccine injection combined with anti-rabies immune globulin (rabies immune globulin, RIG). The two types of RIG currently in use are human rabies immune globulin (HRIG) and equine rabies immune globulin (ERIG). ERIG has severe side effects and inhibits the ...

AI Technical Summary

Problems solved by technology

However, most McAbs are of mouse origin, and the heterogeneous reaction of mouse McAbs greatly limits the application of McAbs as therapeutic agents in humans.

As an antibody component, immunoglobulin (Vaccinia immune globulin, VIG) mainly comes from the immune serum of donors (convalescent patients), and it takes a lot of manpower and financial resources to obtain positive serum and pass the safety test, which makes its mass production difficult. Restricted, and because it comes from serum, it is prone to infection of blood-borne diseases

Images